Recent studies have shown that cerebellar atrophy may be linked to the adverse effects of Dilantin (phenytoin), which has spurred major concern in the medical community.

Since the early 1990s, cerebellar degeneration became associated with the adverse effects of Dilantin with later studies finding a similar correlation.

The alleged correlation between cerebellar atrophy and the adverse effects of Dilantin was first indicated by a study published in 1994, which was published in the Annals of Neurology.

The study had observed five epileptic patients that were prescribed Dilantin and had allegedly developed cerebellar atrophy soon after. While none of the patients had experienced seizures, they had reportedly suffered cerebellar degeneration.

According to the researchers, the Dilantin patients had significantly smaller cerebelli compared to non exposed patients. The cerebellar atrophy had been diagnosed after reviewing diagnostic images, which showed the cerebellar damage.

Later studies had found a similar correlation, with the results indicating that long-term Dilantin exposure increases the likelihood of cerebellar atrophy.

One of these studies was published in 2003 in the medical journal Seizure, with researchers analyzing the potential risk of cerebellar atrophy in conjunction with the adverse effects of Dilantin.

The study had reportedly consisted of 100 epilepsy patients who were prescribed phenytoin for over two months, with the results measured through MRI scans.

Overview of Dilantin Cerebellar Atrophy

Dilantin was approved by the FDA in 1953 to prevent grand mal and complex partial seizures in adult epileptic patients, and it is often prescribed for off-label treatment purposes like anxiety control and stabilizing moods.

Dilantin works by slowing down the electrical signals in the brain, which prevents the onset of seizures. Dilantin is one of the oldest and most prescribed antiepileptic medications in the United States but has become associated with a number of serious side effects like cerebellar atrophy.

Cerebellar atrophy is described as the degeneration of the cerebellum and is also called focal cerebral atrophy. Whether or its focal or generalized, cerebral atrophy can be devastating for patients because it means vital brain functions are losing neurological connections.

Cerebellar atrophy impacts the cerebellum, which causes problems with movement and speech including:

• Unsteady or Lurching Walking Gait
• Slow, Unsteady, or Jerky Movements in Arms or Legs
• Slow and Slurred Speech
• Nystagmus (Small Rapid Eye Movements)
• Memory Loss
• Double Vision
• Nausea or Vomiting
• Decreased Appetite

It is important that cerebellar atrophy symptoms are similar to a stroke, which also includes the problems with coordination and speech problems. The adverse effects of Dilantin primarily affect stability and movement, with the concern of cerebellar atrophy also causing complications with voluntary movements.

Treatment for cerebellar atrophy varies between patients, but it often involves physical therapy or drug prescription. It is important to note that cerebellar atrophy damage cannot be reversed, so patients experiencing the adverse effects of Dilantin should consult their doctor.

This medication is manufactured by Pfizer Inc., which is facing a lawsuit investigation for allegedly failing to warn the public against the adverse effects of Dilantin.

Patients who may have developed Dilantin cerebellar atrophy may be able to file legal action to seek compensation for medical damages.